Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kit for predicting the risk of acute mountain sickness through the expression level of circulating microrna-449b-3p

A microRNA-449b-3p, expression level technology, applied in the direction of DNA/RNA fragment, recombinant DNA technology, microbial determination/inspection, etc., can solve the problem of unseen AMS onset risk, achieve good prediction efficiency and reduce the threat. Effect

Active Publication Date: 2020-09-01
ARMY MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there is no report on the correlation between circulating microRNAs and AMS susceptibility
[0006] There is no report on detecting the expression level of microRNA-449b-3p in blood to predict the risk of AMS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kit for predicting the risk of acute mountain sickness through the expression level of circulating microrna-449b-3p
  • A kit for predicting the risk of acute mountain sickness through the expression level of circulating microrna-449b-3p
  • A kit for predicting the risk of acute mountain sickness through the expression level of circulating microrna-449b-3p

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Correlation between the expression of microRNA-449b-3p in plasma samples and the risk of AMS

[0020]1. Material and Specimen Collection Description

[0021] Plasma samples of AMS-susceptible individuals were collected from 41 AMS patients who entered the plateau rapidly before entering the plateau. Plasma samples of normal people were collected from 46 cases of normal healthy people who entered the plateau rapidly before entering the plateau. The diagnosis of AMS was confirmed by the International Common Diagnostic Criteria-Lake Lewis Score. All the population did not take any preventive medicine before blood sampling. A total of 2ml of blood was collected in EDTA-Na anticoagulant tubes for each sample.

[0022] 2. Sample processing and RNA extraction

[0023] Within 10 minutes after venous blood collection, centrifuge at 3000×g at 25°C for 10 minutes, use RNase-free and bacteria-free tips to take the upper plasma layer and store it in RNase-free and bact...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a microRNA marker for detecting people susceptible to acute mountain sickness, and applications of the microRNA marker in preparing a kit for predicating the onset risk of acute mountain sickness. According to the scheme, the methods including the real-time fluorescent quantitative PCR are adopted for detecting the microRNA-449b-3p molecule in the plain plasma of the tested people, the expression level of the microRNA-449b-3p molecule is utilized for predicating the onset risk of the acute mountain sickness, and the microRNA as the molecular marker has the features of strong specificity, high sensitivity, noninvasion, convenience and the like, and is particularly suitable for carrying out large-scale screening on the people susceptible to acute mountain sickness on the plain.

Description

technical field [0001] The invention relates to a detection kit, in particular to a method for predicting the risk of acute mountain sickness through the expression level of circulating microRNA-449b-3p in plain plasma, so as to evaluate the susceptibility of human body to acute mountain sickness. Background technique [0002] Acute mountain sickness (acute mountain sickness, AMS), also known as acute mild altitude sickness, occurs in people who have lived in low altitude areas for a long time, 1-3 days after rapidly entering a plateau above 2500m without adapting to the new environment It produces a series of symptoms including insomnia, headache, dizziness, loss of appetite, emotional disturbance and vomiting, among which severe headache is a typical symptom of AMS. The incidence of AMS is as high as 50% to 85% depending on the ascent rate and specific altitude (Bartsch P and Swenson E R (2013), Clinical practice: Acute high-altitude illnesses, "N Engl J Med", 368(24), 22...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883C12N15/11
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 徐刚黄河高钰琪刘宝陈建
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com